Compare AIMD & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIMD | HIND |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 11.1M |
| IPO Year | 2008 | 2016 |
| Metric | AIMD | HIND |
|---|---|---|
| Price | $1.24 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | ★ 4.0M | 11.3K |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | N/A | ★ N/A |
| Revenue | $124,157.00 | ★ $319,714.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $145.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 498.95 | 24.43 |
| 52 Week Low | $0.43 | $1.45 |
| 52 Week High | $3.88 | $5.88 |
| Indicator | AIMD | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 60.79 | 18.42 |
| Support Level | $0.50 | N/A |
| Resistance Level | $1.75 | $2.31 |
| Average True Range (ATR) | 0.30 | 0.10 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 51.47 | 4.58 |
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.